According to The Insight Partners – The global clinical trials market is on a strong upward trajectory, reflecting the accelerating pace of medical innovation worldwide. The clinical trials market size is projected to reach US$ 73.33 billion by 2031, rising from US$ 43.37 billion in 2023, registering a compound annual growth rate (CAGR) of 6.8% during 2023–2031. As the pharmaceutical and biotechnology industries push boundaries, clinical trials remain the critical bridge between scientific discovery and patient care.
Clinical Trials Market Drivers: What Is Fueling the Growth?
The clinical trial market is primarily driven by continuous efforts made by pharmaceutical, biotechnology, and medical device companies for product innovations. Other contributing factors include the globalization of clinical trials, rapid advancements in associated technologies, and an increase in demand for contract research organizations (CROs) for conducting clinical trials.
One of the most compelling growth engines is the sheer volume of trials being initiated globally. According to the National Library of Medicine (NLM), approximately 52,000 new studies were registered with ClinicalTrials.gov in 2020, and the number climbed to around 58,000 in 2023. In January 2023, the NLM reported 38,837 active clinical trials in the US and 105,172 active trials worldwide.
Get Sample PDF @ https://www.theinsightpartners.com/sample/TIPRE00006203
The increasing reliance on outsourcing is also reshaping the landscape. To avoid errors due to improper execution, many research-based organizations outsource clinical trials to CROs, which assist in successfully implementing trials through high-quality facilities and deep subject matter expertise. According to Thermo Fisher Scientific, in 2022, CROs executed approximately three out of four clinical trials.
Emerging Opportunities: Decentralized and Hybrid Trials
Perhaps the most transformative shift in the industry is the adoption of decentralized clinical trials (DCTs). In DCTs, digital technologies are used to enable remote data collection and monitoring, along with streamlined communications between investigators and participants. The COVID-19 pandemic accelerated this shift significantly, forcing sponsors to find alternatives to traditional in-person trial models.
According to data from McKinsey, approximately 70% of potential participants for clinical trials reside away from trial sites, meaning decentralization broadens trial access to reach a significantly larger and more diverse pool of patients.
Hybrid trials are also gaining traction. Hybrid clinical trials allow sponsors to strategically incorporate DCT elements into study designs, offering unprecedented flexibility, which is redefining the industry landscape.
Market Segmentation Highlights
Based on study design, the market is bifurcated into interventional trials and expanded access trials, with the interventional trials segment holding a larger market share in 2023. By indication, the oncological conditions segment held the largest market share in 2023. Based on phase, the Phase II segment held the largest market share in 2023.
Geographic Dominance: North America Leads
North America dominated the clinical trials market in 2023. Nearly half of all clinical trials are conducted in the US, which has become the leading clinical research destination due to its established medical infrastructure, rapid approval timelines, a favorable regulatory framework, and globally accepted clinical trial-generated data. A WHO report states that the US had the highest number of clinical trials, with 157,618 trials in 2021.
Get Full Copy of This Report @ https://www.theinsightpartners.com/buy/TIPRE00006203
Key Industry Players and Recent Developments
Leading players operating in the clinical trials market include IQVIA Holdings Inc., Parexel International Corporation, IXICO Plc, Charles River Laboratories Inc., ICON Plc, WuXi AppTec Co. Ltd., Syneos Health Inc., Thermo Fisher Scientific Inc., Oracle Corp., and Medpace, among others.
Strategic partnerships are driving innovation within the sector. Parexel and Palantir Technologies entered into a multiyear strategic partnership to leverage artificial intelligence for enhanced, accelerated, safe, and effective clinical trials worldwide, with Parexel utilizing Palantir’s Foundry and Artificial Intelligence Platform to power its clinical data platform.
Future Outlook
AI-driven clinical trials are expected to emerge as a prime trend in the market in the coming years. Combined with the ongoing expansion of decentralized models and increased CRO collaboration, the clinical trials market is positioned for sustained, significant growth through 2031 — playing a pivotal role in delivering safer, more effective treatments to patients worldwide.
Top Trending Reports @
Clinical Trial Imaging Market Analysis and Opportunities by 2028
Clinical Trial Supplies Market Share, Demand & Growth by 2034
Virtual Clinical Trials Market Share and Forecast by 2034
About Us –
The Insight Partners provides comprehensive syndicated and tailored market research services in the healthcare, technology, and industrial domains. Renowned for delivering strategic intelligence and practical insights, the firm empowers businesses to remain competitive in ever-evolving global markets.
Contact Us:
Contact Person: Ankit Mathur
E-mail: [email protected]
Phone: +1-646-491-9876
Also Available in : Korean German Japanese French Chinese Italian Spanish
